Structural and functional dissection of the cytoplasmic domain of the transmembrane adaptor protein SIT (SHP2‐interacting transmembrane adaptor protein)

SIT (SHP2‐interacting transmembrane adaptor protein) is a recently identified transmembrane adaptor protein, which is expressed in lymphocytes. Its structural properties, in particular the presence of five potential tyrosine phosphorylation sites, suggest involvement of SIT in TCR‐mediated recruitme...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of immunology Vol. 31; no. 6; pp. 1825 - 1836
Main Authors Pfrepper, Klaus‐Ingmar, Marie‐Cardine, Anne, Simeoni, Luca, Kuramitsu, Yasuhiro, Leo, Albrecht, Spicka, Jiri, Hilgert, Ivan, Scherer, Jeanette, Schraven, Burkhart
Format Journal Article
LanguageEnglish
Published Weinheim WILEY‐VCH Verlag GmbH 01.06.2001
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:SIT (SHP2‐interacting transmembrane adaptor protein) is a recently identified transmembrane adaptor protein, which is expressed in lymphocytes. Its structural properties, in particular the presence of five potential tyrosine phosphorylation sites, suggest involvement of SIT in TCR‐mediated recruitment of SH2 domain‐containing intracellular signaling molecules to the plasma membrane. Indeed, it has recently been demonstrated that SIT inducibly interacts with the SH2‐containing protein tyrosine phosphatase 2 (SHP2) via an immunoreceptor tyrosine‐based inhibition motif (ITIM). Moreover, SIT is capable to inhibit TCR‐mediated signals proximal of activation of protein kinase C. However, inhibition of T cell activation by SIT occurs independently of SHP2 binding. The present study was performed to further characterize the molecular interaction between SIT and intracellular effector molecules and to identify the protein(s) mediating its inhibitory function. We demonstrate that SIT not only interacts with SHP2 but also with the adaptor protein Grb2 via two consensus YxN motifs. However, mutation of both Grb2‐binding sites also does not influence the inhibitory function of SIT. In contrast, mutation of the tyrosine‐based signaling motif Y168 ASV completely abrogates the ability of SIT to inhibit T cell activation. Co‐precipitation experiments revealed that the tyrosine kinase p50csk could represent the negative regulatory effector molecule that binds to this motif.
Bibliography:The first two authors contributed equally to this work.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0014-2980
1521-4141
DOI:10.1002/1521-4141(200106)31:6<1825::AID-IMMU1825>3.0.CO;2-V